Skip to main content
32 search results for:

Saxagliptin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-16-2019 | Nephropathy | News | Article

    Dapagliflozin–saxagliptin 'attractive' for type 2 diabetes with kidney disease

    Dapagliflozin, with or without saxagliptin, reduces albuminuria in people with type 2 diabetes and moderate-to-severe chronic kidney disease when used in combination with antihypertensive treatments, DELIGHT study data show.

  2. 05-25-2018 | Oral combination medications | Article

    Characterization of the open-label lead-in period of two randomized controlled phase 3 trials evaluating dapagliflozin, saxagliptin, and metformin in type 2 diabetes

    Mathieu C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0445-x

  3. 06-28-2017 | Topic page

    Saxagliptin_Metformin

  4. 08-16-2018 | DPP-4 inhibitors | Review | Article

    Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

    Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z

  5. 06-12-2018 | Empagliflozin | Article

    Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

    In this work, we aimed to assess the relative treatment effects of empagliflozin versus sitagliptin and saxagliptin (dipeptidyl peptidase-4 (DPP-4)

  6. 09-21-2016 | Heart failure | Article

    Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes

    Fitchett DH, Udell JA, Inzucchi SE. Eur J Heart Fail  2017; 19: 43–53. doi: 10.1002/ejhf.633

  7. 04-17-2018 | DPP-4 inhibitors | At a glance | Article
    Updated July 2019

    Round-up of the DPP-4 inhibitor CV outcome trials

    Of concern, saxagliptin was associated with a significant increase in the rate of hospitalization for heart failure, at 3.5% versus 2.8%.

  8. 11-29-2012 | Post-transplant diabetes mellitus | Review | Article

    Management of post-transplant diabetes

    Therasse A, Wallia A, Molitch ME. Curr Diab Rep 2013; 13: 121–129. doi: 10.1007/s11892-012-0346-8

  9. 06-29-2020 | SGLT2 inhibitors | News | Article

    CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

    Sitagliptin was the most common DPP-4 inhibitor (49% of total exposure time), followed by linagliptin (20%), and saxagliptin (11%).

  10. 02-05-2018 | Cardiovascular outcomes | News | Article

    Low BP may flag cardiac risk in diabetes patients

    The associations were independent of multiple variables including medical history, diabetes duration, glycated hemoglobin levels, receipt of saxagliptin versus placebo, and the cardiac biomarkers N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin-T (hsTnT).

  11. 06-12-2017 | Medications | News | Article

    Research round-up: medications for type 2 diabetes

    He reported that HbA1c values fell from 8.8% to 7.3% in the 232 patients given triple therapy (metformin plus saxagliptin plus dapagliflozin) and from 8.9% to 7.6% in the 229 given dual therapy (metformin plus sitagliptin), which was a significant difference in favour of triple therapy.

  12. 01-31-2020 | Cardiovascular outcomes | News | Article

    Cardiovascular risks, benefits of different diabetes drugs quantified

    There was also no significant association between the individual DPP-4 inhibitors and CV outcomes, with the exception of saxagliptin, which increased heart failure risk by 22%.

  13. 09-28-2016 | Pancreatitis | News | Article
    News in brief

    Pancreatitis risk small but real with gliptin treatment

    Type 2 diabetes, pancreatitis, gliptin, saxagliptin, alogliptin, sitagliptin, SAVOR-TIMI 53, EXAMINE, TECOS

  14. 08-06-2019 | Metformin | News | Article

    Support for metformin cardioprotective effect

    The SAVOR-TIMI 53 analysis, reported in Circulation by Brian Bergmark (Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA) and colleagues, involved 12,156 people with type 2 diabetes who were randomly assigned to receive saxagliptin or placebo.

  15. 05-22-2019 | Sulfonylureas | Editorial | Article

    The CAROLINA trial: Make or break for sulfonylureas?

    Cardio-renal benefit and safety Linagliptin, sitagliptin, and alogliptin have proven cardiovascular safety; however, saxagliptin is associated with an increased risk of hospitalization for heart failure.

  16. 06-21-2018 | Hypoglycemia | Review | Article

    Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

    Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

  17. 06-05-2018 | Cardiovascular outcomes | Review | Article

    Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

    Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

  18. 06-01-2018 | DPP-4 inhibitors | Article

    Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

    Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.